Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843
Case Report
Nifekalant Hydrochloride, a Novel Class III Antiarrhythmic Agent, Suppressed Postoperative Recurrent Ventricular Tachycardia in a Patient Undergoing Coronary Artery Bypass Grafting and the Dor Approach
Makoto SaharaKouichi SagaraTakeshi YamashitaHiroyuki IinumaLong-Tai FuHiroshi Watanabe
Author information
JOURNAL FREE ACCESS

2003 Volume 67 Issue 8 Pages 712-714

Details
Abstract

A patient with 3-vessel coronary artery disease and left ventricular aneurysm underwent coronary artery bypass grafting combined with the Dor approach. Five days later, ventricular tachycardia following short-coupled ventricular premature contractions suddenly occurred and was not responsive to class IB drugs (lidocaine and mexiletine), requiring frequent electrical cardioversion. After the administration of a novel class III drug, nifekalant hydrochloride, this electrical storm of ventricular tachycardia was completely suppressed together with the disappearance of ventricular premature contractions. Nifekalant hydrochloride (MS-551), a pure K+ channel blocker, might be effective for postoperative recurrent ventricular tachyarrhythmias that are refractory to other antiarrhythmic agents. (Circ J 2003; 67: 712 - 714)

Content from these authors
© 2003 THE JAPANESE CIRCULATION SOCIETY
Previous article Next article
feedback
Top